...Euronext:SAN; NYSE:SNY, Paris, France) in up to 450 healthy adults. The trial is funded by VaxInnate’s... ...Advanced Research and Development Authority (BARDA) (see BioCentury, March 7, 2011 & March 9, 2015). VaxInnate Corp....
...The contract extension will provide the remaining $53 million in funding through February 2016. VaxInnate... ...2Q15; a Phase I and Phase II trial of VAX161C; and to prepare commercial formulations. VaxInnate... ...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....
...tolerated with mild to moderate arm pain reported as the most common adverse event. Additionally, VaxInnate... ...mean seroprotection rates of >90% for each of the 4 vaccine components at day 21. VaxInnate Corp....
...intramuscular VAX2012Q in up to 320 healthy volunteers ages 18-40. The trial is funded by VaxInnate's... ...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....
...Euronext:SAN; NYSE:SNY, Paris, France) in up to 450 healthy adults. The trial is funded by VaxInnate’s... ...Advanced Research and Development Authority (BARDA) (see BioCentury, March 7, 2011 & March 9, 2015). VaxInnate Corp....
...The contract extension will provide the remaining $53 million in funding through February 2016. VaxInnate... ...2Q15; a Phase I and Phase II trial of VAX161C; and to prepare commercial formulations. VaxInnate... ...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....
...tolerated with mild to moderate arm pain reported as the most common adverse event. Additionally, VaxInnate... ...mean seroprotection rates of >90% for each of the 4 vaccine components at day 21. VaxInnate Corp....
...intramuscular VAX2012Q in up to 320 healthy volunteers ages 18-40. The trial is funded by VaxInnate's... ...a recombinant influenza vaccine that combines influenza and bacteria proteins (see BioCentury, March 7, 2011). VaxInnate Corp....